SCHEMBL5162808

SCHEMBL5162808

CCCCC(CC)COC(=O)CC(=O)c1cc2ccccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
CYP3A4 P08684 2/20 0.50
CA2 P00918 1/20 0.50
HDAC3 O15379 1/20 0.48
TAS1R3 Q7RTX0 3/20 0.48
TAS1R1 Q7RTX1 3/20 0.48
LMNA P02545 2/20 0.46
TSHR P16473 2/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
MAPT P10636 3/20 0.45
TP53 P04637 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
MAPK1 P28482 2/20 0.43
HPGD P15428 2/20 0.43
AGTR1 P30556 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4502411 0.80 MAPT (0.57) ALDH1A1TAS1R3TAS1R1TSHRMAPT
SCHEMBL7097300 0.78 ALDH1A1 (0.52) ALDH1A1CYP3A4CA2HDAC3LMNA
SCHEMBL5162445 0.78 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2HDAC3LMNA
SCHEMBL1201268 0.78 ALDH1A1 (0.60) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160628 0.76 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2HDAC3TAS1R3
SCHEMBL7139276 0.76 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160040 0.76 ALDH1A1 (0.53) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5162754 0.76 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2TAS1R3TAS1R1
SCHEMBL5163100 0.76 FLT3 (0.57) ALDH1A1TAS1R3TAS1R1TSHRTDP1
SCHEMBL23212935 0.75 ALDH1A1 (0.54) ALDH1A1CYP3A4CA2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885CYP3A4 7/4885CA2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.